0001556247-13-000004.txt : 20130919
0001556247-13-000004.hdr.sgml : 20130919
20130919171624
ACCESSION NUMBER: 0001556247-13-000004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130917
FILED AS OF DATE: 20130919
DATE AS OF CHANGE: 20130919
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER RD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591-6707
BUSINESS PHONE: 9143477000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Van Plew Daniel P
CENTRAL INDEX KEY: 0001411984
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 131106138
MAIL ADDRESS:
STREET 1: REGENERON PHARMACEUTICALS, INC.
STREET 2: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2013-09-17
0
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001411984
Van Plew Daniel P
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
0
1
0
0
SVP & Gen Mgr IOPS
Common Stock
2013-09-17
4
M
0
52500.0
16.8
A
63236
D
Common Stock
2013-09-17
4
F
0
2992.0
294.75
D
60244
D
Common Stock
2013-09-17
4
F
0
25531.0
294.75
D
34713
D
Common Stock
2013-09-18
4
S
0
3777.0
298.28
D
30936
D
Common Stock
2013-09-18
4
S
0
2800.0
299.34
D
28136
D
Common Stock
2013-09-18
4
S
0
2600.0
300.62
D
25536
D
Common Stock
2013-09-18
4
S
0
1400.0
301.42
D
24136
D
Common Stock
2013-09-18
4
S
0
600.0
303.01
D
23536
D
Common Stock
2013-09-18
4
S
0
1444.0
304.16
D
22092
D
Common Stock
2013-09-18
4
S
0
3556.0
305.14
D
18536
D
Common Stock
2013-09-18
4
S
0
3600.0
306.4
D
14936
D
Common Stock
2013-09-18
4
S
0
3200.0
307.28
D
11736
D
Common Stock
2013-09-18
4
S
0
1000.0
308.26
D
10736
D
Common Stock
1363
I
By 401(k) Plan
Non-Qualified Stock Option (right to buy)
16.8
2013-09-17
4
M
0
52500.0
0.0
D
2011-12-31
2018-12-17
Common Stock
52500
0
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 3,777 shares of Company stock on September 18, 2013 at prices ranging from $297.77 to $298.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price.
Represents volume-weighted average price of sales of 2,800 shares of Company stock on September 18, 2013 at prices ranging from $298.87 to $299.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price.
Represents volume-weighted average price of sales of 2,600 shares of Company stock on September 18, 2013 at prices ranging from $299.93 to $300.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price.
Represents volume-weighted average price of sales of 1,400 shares of Company stock on September 18, 2013 at prices ranging from $300.96 to $301.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price.
Represents volume-weighted average price of sales of 600 shares of Company stock on September 18, 2013 at prices ranging from $302.53 to $303.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price.
Represents volume-weighted average price of sales of 1,444 shares of Company stock on September 18, 2013 at prices ranging from $303.76 to $304.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price.
Represents volume-weighted average price of sales of 3,556 shares of Company stock on September 18, 2013 at prices ranging from $304.77 to $305.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price.
Represents volume-weighted average price of sales of 3,600 shares of Company stock on September 18, 2013 at prices ranging from $305.88 to $306.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price.
Represents volume-weighted average price of sales of 3,200 shares of Company stock on September 18, 2013 at prices ranging from $306.96 to $307.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price.
Represents volume-weighted average price of sales of 1,000 shares of Company stock on September 18, 2013 at prices ranging from $307.97 to $308.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price.
The option became exercisable with respect to all shares underlying the option on December 31, 2011, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2011.
/s/**Daniel P. Van Plew
2013-09-19